ClinicalTrials.gg
CompletedNCT03337620Updated Jan 5, 2024

Efficacy and Safety of Tx360® Transnasal Sphenopalatine Ganglion Block in the Treatment of Chronic Migraine

A Phase 3 interventional study of Tx360 in Headache, Migraine, sponsored by Tian Medical Inc.. Completed at 11 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-01-05.

Sponsored by Tian Medical Inc. · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Nov 2023, 3 years ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
174
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 696 studies in Migraine Disorders with a site in United States — 93 open to participants now, 115 under way, 27 of them phase 3. Migraine Disorders · United States.

Enrollment
212th of 609
174 · median 78
Started
2017
with 45 others
Phase 3
136 of 696
20 open now
Registered
368th of 696
by date

Among the 696 studies in Migraine Disorders with a site in United States, this one is the 212th largest by enrollment of the 609 interventional ones that give a count, is one of 46 that started in 2017, is one of 136 in phase 3, and was the 368th registered.

Migraine Disorders

1,658 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.

Browse Migraine Disorders studies →

Open to participants now

93 of the 696 studies in Migraine Disorders with a site in United States are open now. Recruiting first, the newest first:

88 more — sign in →

All 93 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 696 studies in Migraine Disorders with a site in United States, or all of them as a file.
02

Study summary

This is a double blind placebo-controlled study which will evaluate the efficacy of bupivacaine compared to saline, delivered by the Tx360® device to the sphenopalatine ganglion (SPG), to treat chronic migraine headache. The Tx360® is a nasal applicator which is cleared through the FDA for transnasal medication delivery, including delivery to the SPG. The SPG has been implicated in a variety of cephalalgias. It is critical to the success of this intervention that the blocking agent be accurately delivered to this area as it is the only non-bony access to the pterygopalatine fossa (PPF). Subjects meeting inclusion/exclusion criteria will receive 12 intranasal treatments to the SPG over a period of 4 weeks with follow-up monthly for an additional 3 months post-treatment.

Read the detailed description

This is a phase III, multi-center, randomized, double-blind, placebo-controlled, prospective, clinical trial examining the outcomes of subjects with chronic migraine headache who are treated with 0.3cc of 0.5% bupivacaine bilaterally vs 0.3cc of sterile water bilaterally, each delivered to the mucosal surface of the SPG through each nare with the Tx360® device.

Subjects must have a current history of ICHD-III beta migraine with > 14 headache days per month (with 8 or more being migraine) in the 3 months prior to the screening visit. Subjects will be required to have a stable history of doses of migraine prophylactic medication for at least 30 days prior to the start of the 28-day screening/baseline phase and for the duration of the study. At Visit 1, the subject will sign the informed consent indicating they are willing to participate in the study. Initially, subjects who meet the study criteria will participate in a 28-day screening/baseline phase. During the 28-day screening/baseline phase, all subjects will be monitored through the use of electronic Daily Headache Diary (DHD) to ensure they continue to meet all inclusion criteria, and none of the exclusion criteria.

If baseline criteria have been met at the end of the 28-day screening/baseline phase, the subject will return to the clinic for Visit 2 to be randomized into one of the two treatment groups and begin the 4-week treatment phase of the study. Subjects who meet all inclusion criteria, and none of the exclusion criteria, will be assigned to a treatment group based on a computerized randomization number produced by a computer software system. One hundred and eighty subjects will be randomized 1:1 to receive 0.3cc of 0.5% bupivacaine bilaterally or 0.3cc of sterile water bilaterally. One member of the staff will allocate study medication, based on the randomization plan, in a blinded fashion to subject, coordinator, and investigator. At Visit 2, the subject will receive the first treatment.

The subject will return to the clinic three times per week for treatments, totaling 12 treatments.

At visit 13, subjects will receive the last treatment and will be transitioned into the post-treatment phase of the study.

The subject will be followed for an additional 3 months during the post-treatment phase for a total of 20 weeks participation in the study. During this post-treatment phase, the subject will maintain the DHD at an 80% participation rate and two monthly phone visits will take place 1 and 2 months post treatment respectively.

The subject will complete the study at Visit 14 to the clinic for final follow-up.

03

Conditions studied

  • Headache, Migraine

Keywords

  • chronic
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects may be included that meet the following criteria:

    1. willing to participate and sign
    2. ability to understand informed consent and study procedures, including able to use the electronic Daily Headache Diary
    3. in general good health based on investigator's judgment
    4. male or female, age must be between 18 to 65 years of age, inclusive
    5. chronic migraine meeting the diagnostic criteria listed in the International Classification of Headache Disorders (ICHD-III beta version, 2013), as follows:

      1. History of frequent headaches suggestive of chronic migraine (at least 15 days per month with 8 or more being migraine) for at least three months prior to screening
      2. Verification of headache frequency through prospectively collected baseline information during the 28-day screening/baseline phase demonstrating headaches at least 15 days, with at least 8 days per month fulfilling any one of the following

        1. Qualify as being a migraine
        2. Relieved by migraine specific acute medications
    6. onset of migraine before age 50
    7. able to differentiate migraine from any other headache they may experience (e.g., tension-type headache)
    8. stable history of migraine at least 3 months prior to screening with headache free periods
    9. not currently taking a migraine preventive OR has been taking a stable dose of a preventive for at least 60 days prior to screening and agrees to not start, stop, or change medication and/or dosage during the study period

      a) subjects on migraine preventative should have stable headache pattern

    10. subject is either not of , as defined in the methods section, or if they are of childbearing potential they agree either to remain abstinent or use (or have their partner use) an acceptable method of for the duration of the study
    11. demonstrated compliance with the electronic Daily Headache Diary during the 28-day screening/baseline phase as defined by entry of headache data on a minimum of 22 to 28 days (80% diary compliance) in or completing the study.

Exclusion criteria

Exclusion Criteria:

Subjects will be excluded that meet the following criteria:

  1. unable to complete headache records (diary) as required by protocol
  2. pregnant, actively trying to become pregnant, or breast-feeding
  3. history of medication overuse (MO) of opioids, or butalbital, as defined by ICHD-III beta criteria in the previous 12 months and/or MO during 28-day screening/baseline phase (Appendix B).
  4. history of hemiplegic migraine, basilar migraine, cervicogenic headache, occipital neuralgia or post-traumatic headache as defined by ICHD-III beta criteria (Post traumatic headache needs to have developed within 7 days of the following: injury to the head, regaining of consciousness following injury to the head, or discontinuation of medications that impair ability to send or report headache following the injury to the head.
  5. has failed greater than 2 migraine preventative medications due to lack of efficacy after adequate trial
  6. received onabotulinumtoxinA for migraine or for any medical or cosmetic reasons requiring injections in the head, face, or neck during the 4 months before screening.
  7. has a planned military deployment within the 6 months post screening
  8. has previously received SPG blocks using the Tx360®device
  9. history of substance abuse and/or dependence within the past 5 years, in the judgment of the Investigator
  10. unstable neurological condition or a significantly abnormal neurological examination with focal signs or signs of increased intracranial pressure, in the judgment of the investigator
  11. suffers from a serious illness, or an unstable medical condition, one that could require hospitalization, or could increase the risk of adverse events, in the judgment of the investigator
  12. any psychiatric condition with psychotic features, and/or any other psychiatric disorder not stable or well controlled, that would interfere in the ability to complete study activities
  13. within the past year, except for basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix that has been successfully treated
  14. nasal septal deformity such as cleft lip and palate, choanal atresia, atrophic rhinitis, rhinitis, or septal perforation
  15. recent nasal/midface trauma (\< 3 months)
  16. nasal or facial fracture
  17. recent nasal/sinus surgery (\< 3 months)
  18. bleeding disorder such as Von Willebrand disease or hemophilia
  19. severe respiratory distress
  20. neoplasm such as Angiofibroma, sinus tumor, granuloma
  21. nasal congestion present more than 10 days with fever (temperature ≥ 100.4 F) and nasal mucous is an abnormal color
  22. skin around and inside the nasal passage that is dry, cracked, oozing, or bleeding
  23. recurrent nose bleeds
  24. allergy to bupivacaine
  25. has a score > 0 on question 9 of PHQ-9 at any visit
  26. received any agents within 30 days prior to Visit 1
  27. plans to participate in another clinical study at any time during this study
  28. have any other conditions that in the judgment of the Investigator would make the subject unsuitable for inclusion, or would interfere with the subject participating
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
174 participants (actual)

Study arms

  • Active comparator
    Bupivacaine

    Bupivacaine is a local anesthestic that will be delivered to the SPG by the Tx360 device.

    Device: Tx360

  • Placebo comparator
    saline

    Saline is being used as a placebo treatment that will be delivered to the SPG by the Tx360 device.

    Device: Tx360

Interventions

  • DeviceTx360

    Tx360 used to deliver active and placebo drug interventions to SPG.

06

What researchers measure

Primary outcomes

  1. Change in Number of Migraine Headaches During Treatment Phase

    Evaluate the efficacy of bupivacaine delivered with the Tx360® device, based on the change in the number of migraine days during treatment.

    Time frame: From 28-day screening/baseline phase to the end of the 4-week treatment phase.

Secondary outcomes

  1. Change in Number of Migraine Headache Days Post-Treatment

    Evaluate the efficacy of bupivacaine delivered with the Tx360® device, based on the change in the number of migraine days post-treatment.

    Time frame: From 28-day screening/baseline to end of one month post-treatment, end of two months post-treatment, and end of three months post treatments (EOS)

  2. Safety/Tolerability of TX360 Device Based on Adverse Effects

    Evaluate the safety and tolerability of the Tx360® device in the prevention of chronic migraine based on reported adverse effects.

    Time frame: Measured per month from end of 28-day screening/baseline phase to end of the 4-week treatment phase, and end of one month post- treatment, end ot two months post-treatment, and end of 3 months post-treatment.(EOS)

Other outcomes

  1. Efficacy Evaluation Based on Change in Mean Headache Severity

    Evaluate the efficacy of bupivacaine vs sterile water delivered with the Tx360® device, based on the change in the mean headache severity.

    Time frame: Measured per month from end of 28-day screening/baseline phase to end of the 4-week treatment phase, and end of one month post- treatment, end ot two months post-treatment, and end of 3 months post-treatment.(EOS)

  2. Efficacy Evaluation Based on Change in Mean Number of Headache Days per Month

    Evaluate the efficacy of bupivacaine vs sterile water delivered with the Tx360® device, based on the change in the mean number of headache days per month.

    Time frame: Measured per month from end of 28-day screening/baseline phase to end of the 4-week treatment phase, and end of one month post- treatment, end ot two months post-treatment, and end of 3 months post-treatment.(EOS)

  3. Comparison of Response Rate

    Compare the response rate of those in bupivacaine vs sterile water delivered with the Tx360® device.

    Time frame: Measured per month from end of 28-day screening/baseline phase to end of the 4-week treatment phase, and end of one month post- treatment, end ot two months post-treatment, and end of 3 months post-treatment.(EOS)

  4. Comparison of Acute Medication Required

    Compare the need between treatment groups for acute medication based on number of doses of acute headache medication taken.

    Time frame: Measured per month from end of 28-day screening/baseline phase to end of the 4-week treatment phase, and end of one month post- treatment, end ot two months post-treatment, and end of 3 months post-treatment.(EOS)

  5. Evaluate Life Impact of Migraine Headaches

    Evaluate the impact of chronic migraine headaches on the subject's life (pain and disability) based on change in Migraine Disability Assessment (MIDAS) scores between treatment groups.

    Time frame: End of 28-day screening/baseline phase and end of 3 months post treatment.(EOS)

  6. Evaluate Disease Management Impact on Change in PROMIS Score

    Evaluate the subject's perceived impact of disease management based on change in Patient-Reported Outcomes Measurement Information System (PROMIS) scores between treatment groups.

    Time frame: Measured from end of 28-day screening/baseline phase and end of 3 months post treatment. (EOS) to end of treatment phase, and end of post treatment.

07

Study locations

11 sites
  • Yale University
    New Haven, Connecticut 06519, United States
  • New England Institute for Clinical Research
    Stamford, Connecticut 06905, United States
  • Eisenhower Army Medical Center
    Fort Gordon, Georgia 30905, United States
  • Crescent City Headache and Neurology Centre
    Chalmette, Louisiana 70043, United States
  • MedVadis Research
    Watertown, Massachusetts 02472, United States
  • Clinvest Research, LLC
    Springfield, Missouri 65810, United States
  • Hudson Medical
    New York, New York 10007, United States
  • North Suffolk Neurology, PC
    Port Jefferson Station, New York 11776, United States
  • Womack Army Medical Senter
    Fort Bragg, North Carolina 28310, United States
  • Preferred Primary Care Physicians
    Pittsburgh, Pennsylvania 15236, United States
  • Lone Star Neurology
    Frisco, Texas 75035, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2017 to primary completion in Nov 2023, 73 months.

Of 114 industry-sponsored phase 3 interventional studies under Migraine Disorders, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 31. This study's 73 months is above that.

Counting every sponsor, half of 140 studies reached it within 19 months; a quarter within 12 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 20, 2017
First posted
Nov 9, 2017
StartActual
Sep 20, 2017
Primary completionActual
Nov 15, 2023
CompletionActual
Dec 29, 2023
Last update
Jan 5, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 5, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03337620
Lead sponsor
Tian Medical Inc.
Collaborators
TAMM Net, Inc., Clinvest Research, LLC, Ki Health Partners. LLC
Responsible party
Sponsor
First posted
Nov 9, 2017
Start date
Sep 20, 2017
Primary completion
Nov 15, 2023
Completion
Dec 29, 2023
Last update
Jan 5, 2024

Study contacts

Tian Xia, MD
study chair · Tian Medical

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion